We improve the lives of patients, caregivers, and their families through scientific exploration and innovation to solve unmet medical needs.
To be a leading, fully integrated, biopharmaceutical company centered on science and innovation with a passionate and relentless pursuit to develop solutions for patients in need.
At Sucampo we value patients, caregivers, and their families first – they provide the central focus for our scientific pursuits.
We value the people that make our organization great – their empowerment will build our legacy, their passion will ensure our lasting success.
We value the communities where we operate, live, and work. We express this value through our commitment to actively engage in our communities.
We value those that invest back in us and our mission. Our shareholders provide us the support to realize our mission. We are accountable to them and to each other.
Together we will act to live our values in our relentless pursuit of our mission.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.